The shorts are manipulating the heck out of this stock. They can because there is no news to trade off of right now. When the test results are released they will be running for the doors. So hang onto your shares as they are trying to lower the share price and make you sell them so they can scoop them up and make money off of them. I have seen this before with DVAX before the ADCOM. After the the 12-1 vote to approve they were trapped and got burned. With that beating they do not have the guts to try it again. ZGNX is a different story for about another week or a little more than that. We should hear no later than 9/29 and I am expecting good results. They will also do a secondary immediately after the $5 or more rise in share price from the results of the Phase 3 test. GLTA as it may be a rough ride until the results are released but the big rise in share price is the big win for us longs.
Dang... wish I grabbed another 1000 shares at $12.85 today!
Zogenix reported that it would be announcing top line results of its Trial I Phase 3 results for treatment of Dravet's Syndrome in the 3rd qtr of 2017. However, I never thought it would be well into the last few weeks of September! Hope this is not a bad omen.
Today is just another classic short day run it up in the morning and take it back down later in the day. I can't wait until the news comes out and they get FRIED just like they did in DVAX. Bulls make money, Bears make money but PIGS they get SLAUGHTERED.
Harry Boxer has posted his Charts of the Day video on ZGNX at TheTechTrader site noting: Zogenix, Inc. (ZGNX) gained 30 cents, or 2.11%, to 14.55, on 1.2 million shares traded on Tuesday. After coming down for a week, it snapped back. I need for it to get to 15.10, or so. If it does that, it could start to run. If it doesn’t, keep an eye on Tuesday’s low at 13.60. That would be your stopping point.
Look at VSAR this morning. Scary
How the hell was I just able to buy 1000 shares of ZGNX for $15 and sell OCT call options for $6.29 reducing my cost basis to $8.71???
GOOD NEWS TODAY .
Investors in Zogenix, Inc. ZGNX need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 15, 2017 $20 Call had some of the highest implied volatility of all equity options today.
There are 10M + intractable epilepsy patients globally: if the drug is very effective and safe as it seems, probably would be able to used in all intractable sub-form of epilepsy? An enormous untappped/underserved market ...
After hours $16.10? Someone knows something big is happening sometime very soon... That "average price target of $25" might be pretty valid after all.
A wild ride today. Hold onto your Hats!
good news 9/19/2017
It's about time, we are going to hit 20 soon !!
3 Biotech Stocks That Could Soar in September
Alnylam, PTC Therapeutics, and Zogenix have major catalysts on the way.
Aug 27, 2017 at 7:27AM
Winter seems to always be coming in Game of Thrones, but here in the real world, autumn is on the way. While the leaves will start falling in September, some biotech stocks could be set to soar.
Quite a few biotechs have important catalysts coming up in the next month. Three biotechs that could especially benefit from big news on the way are Alnylam Pharmaceuticals (NASDAQ:ALNY), PTC Therapeutics (NASDAQ:PTCT), and Zogenix (NASDAQ:ZGNX). Here's what they have in store in September.
Charts in front of hundred dollar bill Image source: Getty Images.
Alnylam stock has soared in 2017, up close to 130% year to date. The biotech has reported positive results from a phase 2 study of experimental hemophilia drug fitusiran. Alnylam also received breakthrough-therapy designation for givosiran in treating acute hepatic porphyrias (a rare nervous system disease) and an influx of cash from partner Sanofi.
But Alnylam should have the biggest news of all coming up in the next few weeks -- potentially even earlier than September. The biotech expects to announce top-line data from its late-stage study of patisiran in treating patients with hereditary ATTR (hATTR) amyloidosis. If those results are positive, Alnylam intends to file for regulatory approval by the end of 2017.
There is a risk, however, that those results won't be as good as desired. Rival Ionis Pharmaceuticals reported concerning side effects in May from its late-stage study of inotersen, a potential competitor to patisiran. But if Alnylam reports solid efficacy without similar serious side effects, expect its stock to take off even more than it already has so far in 2017.
PTC Therapeutics is another biotech stock that's performed well in 2017, with shares up more than 70% year to date. Much of those gains have come in anticipation of an FDA advisory committee meeting scheduled for Sept. 28. The committee will review PTC's regulatory filing for Translarna in treating nonsense Duchenne muscular dystrophy (nmDMD).
The results from this committee meeting should be quite interesting. PTC Therapeutics tried to file for approval of Translarna last year, but the FDA wouldn't accept the company's submission. The company decided to move forward anyway, filing under protest.
Sarepta Therapeutics (NASDAQ:SRPT) already scored a controversial approval for its DMD drug, Exondys 51. With Sarepta's launch of Exondys 51 seemingly going pretty well, PTC Therapeutics wants its chance, too. A positive recommendation by the FDA advisory committee would be huge in the biotech's getting that chance.
Zogenix hasn't soared like Alnylam and PTC Therapeutics have so far this year. In fact, the stock is barely above its price at the start of 2017. That could soon change, though.
The biotech expects to announce results from its late-stage study of ZX008 in treating Dravet syndrome by the end of September. Good news from that study should bode well for another pivotal late-stage study of the drug for the same indication that's close to completing enrollment.
One company that will probably watch what happens with Zogenix intensely is GW Pharmaceuticals (NASDAQ:GWPH). GW Pharma should complete its regulatory filing for Epidiolex in October for treating Dravet syndrome and Lennox-Gastaut syndrome (LGS). Good news for ZX008 could mean that Zogenix and GW Pharma will compete directly against each other in the next few years.
Sinking in September?
Investors should be aware, though, that each of these stocks could just as easily sink in September instead of soar. Clinical results and regulatory decisions aren't always positive.
PTC Therapeutics probably faces the greatest risk. Filing under protest with the FDA isn't a high-probability move. Alnylam could also experience a similar fate as Ionis with its late-stage results. And even if Zogenix gets good news from its first late-stage study for ZX008, there's still another one to go before possibly filing for approval.
The possibility for huge rewards typically comes joined at the hip with the possibility of huge failure. Both exist for Alnylam, PTC, and Zogenix.
10 stocks we like better than Zogenix When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Zogenix wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 5, 2017
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.
What we need is 17-20 before test results, this drug will be 35-50% more effective then Epidiolex....A blind man can see there's only one way but up........time for all The haters to come out, lol....
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.2 In other words, the correlation coefficient of the other stock
Analyst Actions: Mizuho Securities Initiates Coverage on Zogenix with Buy Rating and $28 PT
BY Midnight Trader
400 m market cap with 0 approved drugs = insanity.
FIRST, they drive it up... THEN, they drive it down.... Traders, can't live with them, can't kill 'em!